78 related articles for article (PubMed ID: 15583857)
1. Dysfunction of the RET receptor in human cancer.
Santoro M; Carlomagno F; Melillo RM; Fusco A
Cell Mol Life Sci; 2004 Dec; 61(23):2954-64. PubMed ID: 15583857
[TBL] [Abstract][Full Text] [Related]
2. The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation.
Peterson S; Bogenmann E
Oncogene; 2004 Jan; 23(1):213-25. PubMed ID: 14712226
[TBL] [Abstract][Full Text] [Related]
3. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of glial cell line-derived neurotrophic factor and neurturin in RET/GFRalpha1-expressing cells.
Lee RH; Wong WL; Chan CH; Chan SY
J Neurosci Res; 2006 Jan; 83(1):80-90. PubMed ID: 16294336
[TBL] [Abstract][Full Text] [Related]
5. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.
Gujral TS; van Veelen W; Richardson DS; Myers SM; Meens JA; Acton DS; Duñach M; Elliott BE; Höppener JW; Mulligan LM
Cancer Res; 2008 Mar; 68(5):1338-46. PubMed ID: 18316596
[TBL] [Abstract][Full Text] [Related]
6. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.
Sawai H; Okada Y; Kazanjian K; Kim J; Hasan S; Hines OJ; Reber HA; Hoon DS; Eibl G
Cancer Res; 2005 Dec; 65(24):11536-44. PubMed ID: 16357163
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated RET signaling in thyroid cancer.
Castellone MD; Santoro M
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):363-74, viii. PubMed ID: 18502331
[TBL] [Abstract][Full Text] [Related]
8. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
Boulay A; Breuleux M; Stephan C; Fux C; Brisken C; Fiche M; Wartmann M; Stumm M; Lane HA; Hynes NE
Cancer Res; 2008 May; 68(10):3743-51. PubMed ID: 18483257
[TBL] [Abstract][Full Text] [Related]
9. [Study on perineural infiltration in bile duct neoplasm--with special reference to the relationship with RET].
Fukuyoshi I
Hokkaido Igaku Zasshi; 2005 Jan; 80(1):21-30. PubMed ID: 15796028
[No Abstract] [Full Text] [Related]
10. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
11. A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2.
Vanhorne JB; Andrew SD; Harrison KJ; Taylor SA; Thomas B; McDonald TJ; Ainsworth PJ; Mulligan LM
Oncogene; 2005 Feb; 24(6):1091-7. PubMed ID: 15592530
[TBL] [Abstract][Full Text] [Related]
12. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
13. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical localization of RET rearrangements in a Malaysian papillary thyroid carcinoma population.
Omar E; Othman NH
Med J Malaysia; 2003 Aug; 58(3):461-2. PubMed ID: 14750392
[No Abstract] [Full Text] [Related]
15. Subcellular receptor redistribution and enhanced microspike formation by a Ret receptor preferentially recruiting Dok.
Stenqvist A; Lundgren TK; Smith MJ; Hermanson O; Castelo-Branco G; Pawson T; Ernfors P
Neurosci Lett; 2008 Apr; 435(1):11-6. PubMed ID: 18353552
[TBL] [Abstract][Full Text] [Related]
16. The RET proto-oncogene: a potential target for molecular cancer therapy.
Pützer BM; Drosten M
Trends Mol Med; 2004 Jul; 10(7):351-7. PubMed ID: 15242684
[TBL] [Abstract][Full Text] [Related]
17. RET proto-oncogene expression of papillary thyroid carcinomas in Thai patients.
Keelawat S; Shuangshoti S; Assanasen T; Thanakit V; Ruangvejvorachai P; Poumsuk U; Wannakrairot P
J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S5-12. PubMed ID: 17718263
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid induces functional c-Ret tyrosine kinase in human neuroblastoma.
Yamada S; Nomura T; Uebersax L; Matsumoto K; Fujita S; Miyake M; Miyake J
Neuroreport; 2007 Mar; 18(4):359-63. PubMed ID: 17435603
[TBL] [Abstract][Full Text] [Related]
19. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret.
Schlee S; Carmillo P; Whitty A
Nat Chem Biol; 2006 Nov; 2(11):636-44. PubMed ID: 17013378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
